Zhitong Finance App News and Platinum Pharmaceutical-B (02142) announced that the new drug clinical trial (IND) application for HBM7004 (a novel B7H4xCD3 bispecific antibody to treat advanced solid tumors) has been approved by China's National Drug Administration. This is another step forward made by the Group after the US Food and Drug Administration (FDA) approved its IND application to launch the first human phase I clinical trial in the US.

According to reports, HBM7004 is a novel b7H4xCD3 bispecific antibody developed from the Group's proprietary HBICE® platform to provide differentiated solutions for cancer immunotherapy in terms of efficacy and safety. The development of the HBM7004 further highlights the flexible applicability and plug-and-play advantages of the HBICE® platform.

In preclinical studies, HBM7004 showed a mechanism of B7H4-dependent T-cell activation within tumors. In various animal model experiments, HBM7004 showed strong anti-tumor effects, excellent stability in vivo, and low systemic toxicity. Furthermore, in preclinical models, the combination of HBM7004 and B7H4x4-1bb double antibodies had a strong synergetic effect under low effector cell-to-target cell ratio conditions, showing an exciting treatment window.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.